Gilead’s stock has fallen 21% since April 30, underscoring investor questions about remdesivir’s potential
August 31, 2020 at 15:26 PM EDT
In the four months since Gilead Sciences Inc. first received emergency authorization for its experimental COVID-19 drug remdesivir, its stock has done the opposite of what you would expect — it has dropped 21%.
